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Abstract
Introduction/Aims: We aim to describe 12-month functional and motor outcome performance
in a cohort of participants with congenital myotonic dystrophy (CDM).
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Methods: CDM participants performed the Six Minute Walk Test (6MWT), 10 Meter Run, 4
Stair Climb, Grip Strength and Lip Force at baseline and 12 month visits. Parents completed the
Vineland Adaptive Behavior Scale.
Results: Forty-seven participants, aged 0 to 13 years old, with CDM were enrolled. 6MWT, 10
Meter Run and 4 Stair Climb were completed in >85% of eligible participants. The only
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significant difference between mean baseline and 12-month performance was an improvement in
6MWT in children 3–6 years old (p=0.008). This age group also had the largest mean %
improvement in performance in all other timed functional testing. In children >7 years, the slope
of change on timed functional tests decreased or plateaued, with further reductions in performance
in children ≥10 years. Participants with CTG repeat lengths <500 did not perform differently than
those with repeat lengths >1000.
Discussion: 6MWT, 10 Meter Run and 4 Stair Climb were the most feasible measures. Our
findings are consistent with the clinical profile and prior cross-sectional data, helping to establish
reasonable expectations of functional trajectories in this population as well as identifying points in
which therapeutic interventions may be best studied. Further study of outcomes in children >10
years old and <3 years is warranted, but this new information will assist planning of clinical trials
in the CDM population.
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Introduction
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Myotonic dystrophy type 1 (DM1) is an autosomal dominant disease caused by a CTGn
trinucleotide repeat expansion in the 3’UTR of the DMPK gene.(1–3) The repeat length may
expand dramatically between generations, particularly when inherited through the mother,
known as anticipation.(4) Large repeat expansions are associated with symptoms at birth,
known as congenital myotonic dystrophy (CDM),(5) although there is no single repeat length
which alone predicts timing of symptom onset.
CDM represents the most severe form of the disease and is characterized by hypotonia,
feeding difficulties and respiratory distress at birth.(6) Children with CDM experience
weakness and cognitive impairment, with delayed motor milestones and behavioral
difficulties.(6–8) Muscle strength improves in early childhood, with behavioral and cognitive
impairments becoming the predominant symptoms.(9, 10) Eventually symptoms are more
consistent with adult DM1, without correlation to severity of neonatal symptoms.(11) The
timing, rates of change, and points of inflection towards adult DM1 phenotypes are
unknown.
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Given the severity of the disease and complex pathophysiology, CDM is an appealing target
for clinical trials with multiple opportunities for targeted therapeutics. Prior to trial
development a better understanding of CDM disease progression, as well as feasibility and
reliability of outcome measures, is needed. In this study, we aim to 1) describe 12-month
progression of strength and functional outcomes in patients with CDM, 2) compare CDM
outcomes to age-matched normative data, 3) evaluate feasibility of measuring fine motor and
gross motor outcomes in a cohort of CDM patients <3 years old as measured via the
Vineland Adaptive Behavior Scale (VABS).
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Methods
Study Design and Patients
Patients with CDM ages 0–13 years, 11 months old were enrolled in a prospective,
longitudinal, multi-center observational study at the University of Utah, the University of
Western Ontario, Canada, and the NEuroMuscular Omnicentre (NEMO) in Milan, Italy.
Diagnosis of CDM was defined as symptoms of myotonic dystrophy in the newborn period
(<30 days) including hypotonia, respiratory distress, feeding difficulty, or talipes
equinovarus, requiring hospitalization greater than 72 hours, and a genetic test confirming an
expanded trinucleotide (CTG) repeat in the DMPK gene in the child or an affected mother.
An expanded CTG repeat size of greater than 200 repeats in the child was considered
confirmatory for CDM. Participants were excluded if they experienced any other illness that
would interfere with study results as determined by site investigators.

Author Manuscript

Written informed consent was obtained from one parent and verbal assent from children
over the age of 8. Institutional Review Boards approved all study procedures prior to
enrollment of participants at each site.
Normative data was provided by the 1000 Norms Project, (12–14) an observational study
investigating outcome measures of self-reported health and physical function in 1000
healthy individuals aged 3 to 101 years.
Procedures
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For all outcomes, evaluators underwent standardized training, including demonstration of
competency with certified experts. Given pronounced cognitive delays and difficulty with
attention in many CDM patients, sites were permitted to make exceptions to the
administration of testing. For participants unable to follow protocoled instructions after one
trial, aids such as light contact cueing, parent and evaluator encouragement, and provision of
items of interest during the tasks as motivation were allowed.
Functional Motor Testing—Six Minute Walk Testing (6MWT) was performed in
accordance with previously validated protocols.(15, 16) Total distance walked, in meters, was
recorded.
10 Meter Run and 4 Stair Climb were performed as previously documented.(17) A stopwatch
was used to measure time in seconds. For the 4 Stair Climb, the end position with hands at
side was often not fully obtained, thus the timer was stopped once the child was balanced
with both feet at the top of the stairs.

Author Manuscript

Strength Testing—Grip strength was collected using the JAMAR Plus+ digital hand
dynamometer (Sammons Preston, Warrenville, Illinois, USA). Dominant hand was identified
according to parent report. Participants were instructed to squeeze as hard as possible with
hand and forearm in neutral pronation/supination and elbow in 90 degrees of flexion. Three
trials were attempted; the average of the trials is reported. Grip strength was measured in
kilograms and converted to Newtons by standard conversion of 9.807. Normative data was
collected in the same position, with maximal force exerted for 3–5 seconds. Results were
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measured in Newtons using the Citec Hand Held Dynamometer (CT 3001, CIT Technics,
Arnhem, Netherlands.)
Ankle dorsiflexion was collected using a Commander Muscle Tester (PowerTrack II, JTECH
medical, Midvale, Utah, USA). Dorsiflexion strength was assessed with shoes off in the
seated position with the leg flexed over the edge of the table. The evaluator manually
stabilized the ankle joint and placed the myometer over the dorsum of the foot at the
metatarsals. Dorsiflexion with inversion was permitted, due to the difficulty of CDM
patients achieving pure dorsiflexion. Three trials were attempted; the average of the trials is
reported. All measures were converted from kg to N using the aforementioned conversion.
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Lip strength was measured using the Imada DS2 Digital Force Gauge (Imada, Inc.,
Northbrook, Illinois, USA) attached to a Vettex Doubleguard Mouthguard Pee Wee (Model
PW22; Markwort Sporting Goods Co., St. Louis, Missouri, USA) as previously described.
(18) Participants were seated in chairs in the position tin which testing was best tolerated.
Use of the Lip Force Meter was first demonstrated by the clinical evaluator. The meter was
then placed in the participant’s mouth and they were instructed to hold it with their lips and
resist the pulling force from the evaluator for as long as they could with closed lips. An
average of three trials is reported.

Author Manuscript

Vineland Adaptive Behavior Scale—VABS(19) is an instrument evaluating a child’s
adaptive abilities relative to normally developing children. Subcategories of behaviors
include communication (receptive, expressive, written), daily living skills (personal,
domestic, community), socialization (interpersonal relationships, play and leisure, coping
skills) and motor skills (gross motor and fine motor). Surveys were either provided to
participants’ parents for completion or were completed with assistance from a qualified
assessor.
Scores on subdomains are represented as v-scores, calculated from primary norm-referenced
values. V-scores of 1–9 indicate low adaptive levels, 10–12 moderately low, 13–17 adequate,
18–20 moderately high and 21–24 high. Average norm-referenced v-scores are 15±SD 3.
The subdomain scores are compiled as an Adaptive Behavior Composite (ABC) score,
which is then converted to a percentile rank as compared to age-matched normative samples.
Statistical Analysis
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Comparisons between baseline and 12-month performance were assessed using paired ttests. P-values <0.05 were considered significant. Analysis and descriptive statistics were
performed using R statistical software version 3.6.2. Calculations for 6MWT percent of
predicted performance as compared to age-matched healthy individuals were made using the
Geiger equation.(20)

Results
Forty-eight participants with CDM were enrolled. One participant was excluded as he did
not meet criteria. The participant had neonatal respiratory failure but after review of the
clinical context it was not felt to be related to DM1. Data are presented by age group based
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on age at baseline visit: <3 years, 3.0–6.99 years, 7.0–9.99 years and ≥ 10 years. The 1000
Norms Project provided normative data on 204 healthy children, with n=20 for each age 3–9
years and n=16 for each age 10–14 years. Gender, male/female, was equally represented in
each age group.
Baseline characteristics are presented in Table 1. Repeat lengths were available for 40 of 47
participants. One repeat length was reported as 300+ and was thus assigned 300.
Demographics and neonatal clinical characteristics of participants without known repeat
lengths are displayed as part of supplementary materials (Table S1).
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Of the participants with ECG abnormalities deemed clinically significant by study
investigators, one had long PR and wide QRS intervals, two had right ventricular
hypertrophy, one had an unspecified atrial arrhythmia with long PR interval, and one had
tachycardia, T-wave abnormalities, right ventricular hypertrophy and long PR interval.
Feasibility assessments of functional outcomes in those who were able to walk
independently and over the age of 3 years identified an 87% (26/30) completion of the
6MWT, 83% (25/30) of the 10 Meter Run, 93% (28/30) completion of the 4 Stair Climb
ascent portion, and 87% (26/30) of the descent. Results marked invalid were primarily due to
physical limitations. The feasibility of grip strength and lip force measurements was 64%
(25/39) and 51% (20/39), respectively. Invalid results for strength testing were due to
inability to understand directions. Valid ankle dorsiflexion data was only available for 7
participants, and thus is not displayed. There was no valid functional motor data available
for participants less than 3 years of age.
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Baseline to 12-month progression data and associated repeat length are shown in Figure 1.
Mean time between baseline and 12-month visit was 392 days (range 339–536); 15
participants had visits outside of the protocol-defined visit window of 1 year plus or minus
30 days. The mean percent change of all other outcomes from baseline to 12 months is
displayed in Table 2.
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There was a statistically significant difference showing improvement between mean baseline
and 12-month performance on the 6MWT in the participants aged 3–6 years old.
Improvement in performance for the participants aged 7–9 years did not reach statistical
significance. At baseline, CDM participants walked a mean percent predicted distance of
40.9% (3–6y), 52.6% (7–9y), and 62.6% (≥10y), respectively. At 12 months, mean group
performance in children aged <10 years improved, with percent predicted walking distance
of 57.3%, p=0.08 (3–6y) and 64.2% p=0.33 (7–9y); however, on average, children aged ≥10
years had a reduction in predicted distance walked (61.3%, p=0.9). CDM 6MWT
performance as compared to age-matched control is displayed in Figure 2. CDM participants
performed consistently below, or at the lower end of normal, as compared to healthy controls
in the 6MWT, with performance declining away from the normal curve with increasing age.
In all other timed function tests, children aged 3–6 years had the greatest mean %
improvements in performance (Table 2). This improvement was less for children aged 7–9
years, with a very slight worsening of mean performance in the 10 Meter Run. Children

Muscle Nerve. Author manuscript; available in PMC 2021 April 11.

Quigg et al.

Page 6

Author Manuscript

aged ≥10 years had the smallest mean % change in performance in timed function tests with
a worsening in mean performance in 10 Meter Run and 4 Stair Descent.
These patterns were not observed in grip strength or lip force (Table 2). Grip strength in
CDM participants reasonably matched control performance in children aged 3–6 years
(Figure 2). Performance separated away from normative data with increasing age, aside from
two children aged ≥10 years who performed equally to healthy peers.
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VABS Gross Motor and Fine Motor scores, and ABC scores by repeat length are available as
part of supplementary materials (Figure S1). All participants scored below the 80th
percentile of their age-predicted ABC score at both baseline and 12-month visits. Gross
Motor and Fine Motor Subscales are displayed in Figure 3. One participant (age 6.5 at
baseline) achieved a v-score of 18, or moderately high adaptive functioning, in the Gross
Motor subscale at the 12-month visit (an improvement of 10 points from baseline). All other
scores remained below the threshold of ‘adequate’ at both points of testing.
There were 5 participants under the age of 3 for whom data were available. Relative to
baseline assessments, average ABC percentile rank decreased in children aged <3 years.
Two of the five children aged <3 years had reductions in ABC score percentile ranks of at
least 30%. The youngest child showed improvement of less than 5%. The other two
displayed negligible change. None of the children aged <3 years improved in the Fine Motor
Subscale between baseline and 12 months. All five children aged<3 years scored below 13
on the Gross Motor Subscale. Three of 5 had further decline in v-scores at 12 months.

Discussion
Author Manuscript

Longitudinal data on standardized motor outcome measures in children with CDM are not
available. This study fills a significant knowledge gap by providing information on 12month progression in strength, timed motor tests and behavioral outcomes in children with
CDM. Overall, children with CDM perform worse than healthy children of the same age.
When evaluated over the age of 10 years, the gap between children with CDM and those
healthy controls widens. Our observations in the 6MWT, 10 Meter Run and 4 Stair Climb
descent support the trend of improvement in function in younger years, followed by a
plateau or decrease in rates of improvement, before a steady decline in participants greater
than 10 years of age. This finding is consistent with clinical observations and previous
studies.(9–11) Given that only one subgroup had significant change over 12 months, and only
in the 6MWT, outcome assessments at intervals of 12 months or longer appears to be
reasonable. More frequent assessments likely would not reveal significant changes.
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Lip force and grip strength in CDM participants did not mimic this pattern, but were
obscured by some CDM subjects performing notably better than peers. It is also worth
noting that cognitive impairment influenced feasibility of these two measures more than the
functional measures, an important consideration for future clinical trials.
Interestingly, participants with repeat lengths between 500–1000 did not perform differently
than those with repeats >1000. Although repeat length is often considered as a disease
severity marker, the correlation with many disease characteristics is weak and overall the
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repeat size should not be used for prognosis. Continued analysis of progression into older
age ranges merits further study.
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Results from the VABS showed a considerable functional decline in composite score and
both motor subscores for those aged less than 3 years, though our sample size was very
small. VABS did not demonstrate reliable trends across any of the other age groups. This
could be because the scale is parent-reported, or because it does not capture the complexity
of CDM comorbidities. Other comprehensive tools considered for evaluation of our CDM
population included the Bruininks-Oseretsky Test of Motor Proficiency, Second Edition
(BOT-2), though previous cross-sectional data(21) in a CDM population demonstrated such
poor results on the BOT-2, that further use of this tool as a potential clinical trial outcome
measure would be futile. It appears most likely that a different measure, encompassing
multiple functional and behavioral domains specific to myotonic dystrophy, which can be
reliably completed by parent proxy, is needed for better evaluation.
Several limitations should be noted, most importantly the difficulty in obtaining reliable
outcomes from patients with physical, cognitive and behavioral impairments. Due to these
challenges, it is unclear whether functional and motor testing outcomes are a reflection of
true maximum physical effort, or a child’s ability to understand and follow instructions. This
could be overcome by controlling for cognitive function with either IQ or
neuropsychological testing, though reliable data on cognitive measurement selection is not
yet available in this population. Oral aversion, which is recognized clinically in CDM and
many other congenital muscular dystrophies(22), though not directly assessed in this study,
also contributes to difficulties in obtaining reliable measures of orofacial function and should
be further evaluated as a limitation in future investigations.
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Selecting outcomes appropriate for patients across age groups is also challenging, though the
availability of normative data can help to distinguish changes in longitudinal CDM outcome
measurements that would be expected to improve in parallel with childhood development,
from the relative flattening of the slope compared to healthy controls demonstrated in our
cohort. This separation from the normal development curve is distinct from other pediatric
neuromuscular diseases in which there is a frank decline in performance.(23) Regardless, 12month progression data does not paint the whole picture of CDM disease evolution and
progression. More data, over a longer period of time, and in other CDM patient samples are
needed to better characterize longitudinal trends in this patient population, as well as more
detailed investigation into feasibility of functional outcomes as they directly relate to
cognitive impairment.
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For purposes of clinical trial design and enrollment, it would be reasonable to target children
at the plateau point, or the start of the slope of decline, in order to measure clinically
meaningful delay or halt of disease progression. Evaluation of outcomes at 12-month
intervals is also a reasonable timeline for assessment in future trials. These data are
foundational work in moving the field toward selecting the most feasible, reliable and valid
outcome measures for clinical and research work. From this study, functional measures such
as 6MWT, 10 Meter Run and 4 Stair Climb appear to be the most feasible and consistent
with prior cross-sectional data. The CDM community needs progress in understanding
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outcome measures beyond motor measures, such as patient reported outcomes and parent
proxy questionnaires, as well as cognitive and disease severity biomarkers, in order to be
fully ready for evaluating novel therapeutics.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1: Baseline to 12 month Performance with Repeat Length.
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A) 6 Minute Walk; B) 10 Meter Run; C) 4 Stair Climb-Ascent; D) 4 Stair Climb-Descent; E)
Grip Strength; F) Lip Force. Arrows represent individual subject performance. Blunted end
of arrow represents baseline performance. Arrow heads correspond with 12-month visit
performance.
NA = Not Available; s = seconds; m = meters; N = Newtons.
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Figure 2: CDM Participant Performance Compared to Normal Controls.

Author Manuscript

A) 6 Minute Walk; B) Grip Strength.
Controls from the 1,000 Norms Study are represented by shaded circles. Increasing densities
represent overlapping performance. Solid arrows represent individual subject performance.
Blunted end of arrow represents baseline performance. Arrow heads correspond with 12month visit performance.
m= meters; N = Newtons.
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Figure 3: Vineland Adaptive Behavior Scale Gross and Fine Motor Subscales.

A) Gross Motor Subscale; B) Fine Motor Subscale. CDM participant performance from
baseline to 12 month visits. Results above the dashed line (V-score = 13) are considered at
least an “Adequate” level of adaptive functioning.
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Table 1:

Author Manuscript

Baseline Characteristics.
Variable

CDM (n=47 unless otherwise indicated)

Age, years,
Mean ±SD

6.41±3.64

Age group (n)
<3 years of age

8

3–6 years of age

22

7–9 years of age

8

≥10 years of age

9

Gender, n (%)

Author Manuscript

Male

25(53%)

Female

22(47%)

CTGn repeats (n=40)
0–499

4

500–999

10

1000–1499

16

1500–1999

8

2000+

2

Gestational Age, weeks (n=45)

Author Manuscript

<35*

12

35–37

10

8–41

22

>41

1

Respiratory Assistance, weeks (n=34)
Mean ±SD

24.71±42.71

Range

0.3–156

ECG (n=38)
Abnormal, clinically significant findings
yes (n,%)

5 (13%)

no (n,%)

33 (87%)

Age at independent ambulation, months (n=30)†

Author Manuscript

Mean ±SD

25.94±9.99

Range

11–60

*

= Exact gestational age was available for 6 of the 12 participants born before 35 weeks. One participant was born at 29 weeks, the remainder were
born between 30-37 weeks.

†

= 2 children were below 12 months of age at time of evaluation and were excluded from calculation CDM = Congenital Myotonic Dystrophy, SD
= Standard Deviation, ECG = Electrocardiogram
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Table 2:

Author Manuscript

Mean percent change in performance from baseline to 12-month visit.

Author Manuscript

Variable

3–6 years

7–9 years

≥10 years

6 Minute Walk

n= 11
+35.92%
p=0.008

n=7
+12.97%
p=0.059

n= 8
−1.56%
p=0.963

10 Meter Run*

n=11
−2.05%
p=0.856

n=7
+0.30%
p=0.962

n=7
+14.29%
p=0.199

4 Stair Climb*, ascent

n=12
−55.33%
p=0.138

n=8
−26.55%
p=0.102

n=8
−6.66%
p=0.343

4 Stair Climb*, descent

n=10
−28.31%
p=0.111

n=8
−13.72%
p=0.309

n=8
+5.92%
p=0.565

Grip Strength

n=11
+3.75%
p=0.777

n=6
+0.77%
p=0.946

n=8
+23.12%
p=0.091

Lip Force

n=9
+34.36%
p=0.308

n=4
−1.06%
p=0.978

n=7
+15.34%
p=0.401

*

= Negative values indicate faster completion, or better performance, of 10 Meter Run and 4 Stair Climb
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